1. P587 Disease severity in the INFLAMMATORY BOWEL DISEASES: Do patients and physicians agree?. (21st January 2022) Authors: Timmer, A; de Sordi, D; Neuser, J; Seibel, K; Hensel, A; Schmidt-Lauber, M; Allgayer, H; Klebl, F; Obermeier, F; Jessen, P; Schnoy, E; Helwig, U; Morgenstern, J; Leifeld, L; Schmidt, S; Meinhardt, C; Maaser, C; Bästlein, E; Bokemeyer, A; Graefe, U Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i524 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics. (15th January 2020) Authors: Bokemeyer, B; Plachta-Danielzik, S; Sobotzki, C; Mohl, W; Hoffstadt, M; Krause, T; Atreya, R; von der Ohe, M; Graefe, U; Trentmann, L; Eisold, M; Linde, A; Franzenburg, S; Moser, M; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S584 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗